about
Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization.High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization.Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experienceIntra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial[Renal cell carcinoma and prognostic factors][The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma]Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinomaCementoplasty for painful bone metastases: a series of 42 casesVolumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?Sorafenib- or 90Y-loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenibMedical treatment for cholangiocarcinoma
P50
Q35888586-5A03563C-B4C5-44C2-80F4-A485E947A5E4Q37565602-87013C62-5B8E-445E-B8AE-6C93DC7480A4Q38817589-52119F0A-92CD-4CA5-A7C4-4190FA316375Q38931433-D005E944-7BCB-413B-82D0-6809EDC76205Q39398836-673DBF5F-26DC-4BFC-92A5-2EC1D17F8F57Q39743925-4BB8AC3D-27D0-40F9-A589-8203756BD364Q40444455-B9586FBE-C6C2-41F6-8760-0B844B056B7EQ47682416-0DD1E81C-0A95-46E1-AA63-FAB02209C3ABQ51301390-28B7CBB6-561C-42B0-B1DF-005DB0D8AFCBQ53656092-270A630E-8838-43F7-9AA2-F68F79EA72A2Q54578237-13F2B8E5-7AD2-401F-9214-7CF7584D402AQ58102813-5AA99279-CF4F-4860-B743-A7810C5DE0EEQ58776805-69AA0084-FE45-4C8B-83A1-92A7B0D15747Q82894020-E03EA020-A66D-4BEA-85A3-2DB6FABE6DB9Q82974282-88F08743-ED3A-491C-9B92-1A6D54501746Q83490635-AC156EC0-043A-4EF2-A0A8-D3AD3136909FQ83887449-765D568D-11BB-49F9-8082-755ECD80207AQ86389913-6CBEB604-2D61-46AD-A102-33D3734077C3Q86759427-1720ABE8-D90F-4FE8-B38A-6A85C3328BB5Q90451560-EC66F226-12A7-433E-B621-5C56C4ED2949Q92501716-639E0EFE-DB21-4585-B469-1BF2474E135A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Julien Edeline
@ast
Julien Edeline
@en
Julien Edeline
@es
Julien Edeline
@nl
Julien Edeline
@sl
type
label
Julien Edeline
@ast
Julien Edeline
@en
Julien Edeline
@es
Julien Edeline
@nl
Julien Edeline
@sl
prefLabel
Julien Edeline
@ast
Julien Edeline
@en
Julien Edeline
@es
Julien Edeline
@nl
Julien Edeline
@sl
P1053
F-6852-2013
P106
P21
P31
P3829
P496
0000-0002-8289-7741